FTC Underscores Enforcement Focus on Pharmaceutical Rebates, Fees That Harm Competition
- June 17, 2022
The Federal Trade Commission is ramping up its scrutiny of rebates and fees drug manufacturers pay to pharmacy benefit managers (PBMs) that foreclose competition from lower-priced drug alternatives and harm consumers.
ARTICLE TAGS
You must be logged in to access this content.